Novo Nordisk Nanexa Deal Advances Injectables

Novo Nordisk Nanexa deal gives Novo access to PharmaShell for long-acting injectable programs and shifts trader focus to cardiometabolic R&D.

September 25, 2026·1 min read
View all news articles
Flat-vector depiction of a coated injectable capsule suggesting controlled release and the Novo Nordisk Nanexa deal.

KEY TAKEAWAYS

  • Novo secured a global exclusive license to Nanexa's PharmaShell for up to five development programs.
  • Nanexa stood to receive up to €1.165 billion in contingent payments.
  • Targets monthly and quarterly dosing profiles; Novo will lead development and commercialization.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Novo Nordisk said on Sept. 24, 2026, that it secured a global exclusive license to Nanexa’s PharmaShell drug-delivery platform to pursue up to five long-acting injectable programs for obesity, type 2 diabetes, and other cardiometabolic diseases, expanding its development options.

Deal Terms and Technology

Nanexa announced in a Sept. 24, 2026 press release that it entered a global exclusive license and collaboration agreement granting Novo Nordisk access to its PharmaShell platform. The deal covers up to five development programs targeting obesity, type 2 diabetes, and other cardiometabolic indications. Nanexa is eligible for up to €1.165 billion in contingent payments, including €615 million in upfront and development/regulatory milestones, with the remainder tied to sales milestones and low-single-digit royalties on global net sales. Novo Nordisk will lead global development and commercialization of products arising from the collaboration.

PharmaShell uses atomic layer deposition (ALD) to apply an ultra-thin coating on drug particles, controlling their release over time. The collaboration aims to develop long-acting injectable peptide medicines with monthly and quarterly dosing profiles as targets, not approved schedules.

By securing exclusive rights to PharmaShell and leading development and commercialization, Novo gains technical and commercial control to pursue less-frequent dosing across its cardiometabolic programs.

Nanexa scheduled a live commentary with Chief Executive David Westberg and Chairman Göran Ando for Sept. 25, 2026, at 11:15 a.m. CEST (5:15 a.m. ET).

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

ChatGPT Wallet Launch Expands AI Payments

ChatGPT Wallet Launch Expands AI Payments

ChatGPT Wallet uses tokenized AI agent payments and biometric checks, a development that could shift trader positioning in card networks and merchant tech.

SpaceX Starship Flight 15 Aims for First Dual Recovery

SpaceX Starship Flight 15 Aims for First Dual Recovery

SpaceX Starship Flight 15 targeted the first dual-stage tower catch and Starlink deployment, a technical reusability milestone investors watch.

FAA Nationwide Ground Stop Halts U.S. Departures

FAA Nationwide Ground Stop Halts U.S. Departures

FAA nationwide ground stop halted U.S. departures and exposed airlines to operational disruption that could spur volatility in travel stocks and flows.

Samsung Modine Acquisition Talks Send Modine Shares Up

Samsung Modine Acquisition Talks Send Modine Shares Up

Samsung Modine acquisition talks on Nov. 12-13 spurred an after-hours rally that forced traders to reprice Modine amid AI data-center demand.

U.S. PPI October Remains Elevated

U.S. PPI October Remains Elevated

U.S. PPI October saw cooler monthly growth yet elevated annual inflation, a result traders said could reinforce expectations for restrictive Fed policy.

HawkEye 360 Earnings Rise After Record Q3

HawkEye 360 Earnings Rise After Record Q3

HawkEye 360 earnings rose after a record Q3 and management raised full-year revenue and adjusted-EBITDA guidance, likely shifting analyst models.